SCHEMBL24118262

SCHEMBL24118262

C=C(CCNC(=O)Nc1cccc(Cl)c1)[C@H](C)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.56
▸ EPHX1 P07099 4/20 0.51
▸ EPHX2 P34913 3/20 0.49
▸ CASR P41180 1/20 0.49
▸ MEN1 O00255 5/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ MAPT P10636 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ OPRM1 P35372 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24118279 0.88 MEN1 (0.59) RAB9AMEN1KMT2AMAPTLMNA
SCHEMBL24118254 0.88 FPR2 (0.48) RAB9AMEN1KMT2AMAPTLMNA
SCHEMBL24118405 0.87 KMT2A (0.44) RAB9AMEN1KMT2ALMNANPC1
SCHEMBL23593230 0.83 CYP1A2 (0.50) RAB9ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL24117952 0.82 KMT2A (0.58) RAB9AMEN1KMT2AMAPTLMNA
SCHEMBL24118338 0.80 GCGR (0.46) EPHX2ALDH1A1CNR1
SCHEMBL24118326 0.79 GCG (0.49) RAB9AKMT2ALMNANPC1ALDH1A1
SCHEMBL24118062 0.78 IDO1 (0.54) MEN1KMT2AALDH1A1TP53SMN1; SMN2
SCHEMBL24118042 0.78 IDO1 (0.53) RAB9AMEN1KMT2AMAPTLMNA
SCHEMBL11007034 0.76 MEN1 (0.79) RAB9AMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 RAB9A 2866/4885EPHX1 670/4885EPHX2 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback